Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update (Businesswire) - May 9, 2024 - "PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026. PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of topline data in mid-2025."
P2a data • P2b data • Autoimmune Hepatitis • Immunology • Lupus Nephritis
|